021-51111890
购物车（）
sales@molnova.cn
Panobinostat
CAS No. 404950-80-7
Panobinostat ( LBH-589;LBH589;NVP-LBH589 )
产品货号. M14388 CAS No. 404950-80-7
A potent, broad-spectrum HDAC inhibitor with IC50 of 5-20 nM in cell-free assyas.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥259 | 有现货 |
|
| 10MG | ￥421 | 有现货 |
|
| 25MG | ￥648 | 有现货 |
|
| 50MG | ￥867 | 有现货 |
|
| 100MG | ￥1191 | 有现货 |
|
| 200MG | ￥1515 | 有现货 |
|
| 500MG | ￥3102 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Panobinostat
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述A potent, broad-spectrum HDAC inhibitor with IC50 of 5-20 nM in cell-free assyas.
-
产品描述A potent, broad-spectrum HDAC inhibitor with IC50 of 5-20 nM in cell-free assyas; induces cell-cycle arrest, apoptosis, and histone (H3K9 and H4K8) hyperacetylation, increases mRNA levels of proapoptosis, growth arrest, and DNA damage repair genes including FANCG, FOXO3A, GADD45A, GADD45B, and GADD45G; significantly slows tumor growth derived from Meso and NSCLC cells in vivo models.Blood Cancer Approved
-
同义词LBH-589;LBH589;NVP-LBH589
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC(MOLT-4cells);HDAC(Rehcells)
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number404950-80-7
-
分子量349.43
-
分子式C21H23N3O2
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 57 mg/mL
-
SMILESO=C(NO)/C=C/C1=CC=C(CNCCC2=C(C)NC3=C2C=CC=C3)C=C1
-
化学全称2-Propenamide, N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-, (2E)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Crisanti MC, et al. Mol Cancer Ther. 2009 Aug;8(8):2221-31.
2. George P, et al. Blood. 2005 Feb 15;105(4):1768-76.
3. Scuto A, et al. Blood. 2008 May 15;111(10):5093-100.
2. George P, et al. Blood. 2005 Feb 15;105(4):1768-76.
3. Scuto A, et al. Blood. 2008 May 15;111(10):5093-100.
产品手册
关联产品
-
Merck60
Merck60 (BRD 6929, Compound-60)is a potent, selective and brain-penetrant inhibitor of HDAC1 and HDAC2 with IC50 of 1 nM and 8 nM respectively.
-
CUDC-101
A potent, multi-targeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively.
-
Belinostat
Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.
